Intuitive, a leader in robotic surgery, recently reported positive growth in its full year 2025 (FY25) and Q4 financials. Despite this, the company’s stock has experienced a decline, causing some concern among investors.
During the J.P. Morgan Healthcare Conference in San Francisco, Intuitive revealed that its preliminary FY25 revenues reached approximately $10.06 billion, showcasing a 21% increase from the previous year. In Q4 2025, the company expects revenues of $2.87 billion, reflecting a 19% rise compared to Q4 2024.
CEO Dave Rosa highlighted that Intuitive achieved a milestone of 20 million procedures with its da Vinci robots in Q4 2025. Additionally, he noted that 35% of procedures now occur outside of the US, a significant increase from 17% in 2005. Rosa attributed this success to the dedication of Intuitive’s teams and the company’s long-term investments.
Despite these achievements, Intuitive’s stock saw a 5% decrease on the Nasdaq stock exchange following the financial report. The company’s market cap currently stands at $193.82 billion. One potential reason for the stock decline is Intuitive’s projection of a 13% to 15% increase in da Vinci procedures in 2026, falling below analysts’ expectations.
Analyst Brandon Vazquez from William Blair noted that the stock weakness may be linked to the modest procedure growth forecast for 2026. Moreover, challenges in China’s tender process and the emergence of new robotic competitors in the market have also impacted investor sentiment.
Despite these challenges, Intuitive maintains a strong presence in the Chinese market, holding over 60% market share in 2024. The global robotics market has witnessed new entrants, such as Medtronic’s Hugo, approved for urologic procedures in the US.
In 2025, Intuitive’s robots performed approximately 3.2 million procedures, with the majority conducted on the multi-port platform. The company installed nearly 1900 systems across all platforms, further expanding its reach in the market.
As foreign companies navigate China’s evolving procurement landscape, Intuitive faces new challenges in this key market. The preference for domestic medtech companies in China poses a potential obstacle for Intuitive’s growth strategy in the region.
In conclusion, while Intuitive continues to demonstrate positive growth and innovation in the robotic surgery sector, external factors like market competition and regulatory challenges present ongoing hurdles for the company’s stock performance. Investors will closely monitor Intuitive’s strategies and market positioning in the coming year.
